Mineralys Therapeutics, Inc. Common Stock (MLYS) — Financial Flexibility Index

Latest as of March 2026: -2.68x

Mineralys Therapeutics, Inc. Common Stock (MLYS) has a Financial Flexibility Index of -2.68x as of March 2026. Free cash flow of $-39.47 Million (operating CF $-39.47 Million minus capex $0.00) represents -3% of total liabilities ($14.72 Million). Also explore net asset growth rate of Mineralys Therapeutics, Inc. Common Stoc to track the company's year-over-year net asset growth rate.

Financial Flexibility Index

-2.68x
Free Cash Flow / Total Liabilities

Free Cash Flow

$-39.47 Million
Operating CF − Capex

Total Liabilities

$14.72 Million
USD

Capital Expenditures

$0.00
USD

Mineralys Therapeutics, Inc. Common Stock Financial Flexibility Index (2020–2025)

Historical Financial Flexibility Index trend for Mineralys Therapeutics, Inc. Common Stock across 6 annual periods. Check MLYS capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.

Annual Financial Flexibility Index for Mineralys Therapeutics, Inc. Common Stock (2020–2025)

Year-by-year free cash flow to debt coverage for Mineralys Therapeutics, Inc. Common Stock. For the full company profile including market capitalisation, see Mineralys Therapeutics, Inc. Common Stoc (MLYS) total market value.

Year Flexibility Index Free Cash Flow (USD) Operating CF Total Liabilities YoY Change
2025 -9.42x $-142.40 Million $-142.42 Million $15.11 Million ▲ +17.0%
2024 -11.35x $-166.22 Million $-166.31 Million $14.65 Million ▼ -46.6%
2023 -7.74x $-81.17 Million $-81.17 Million $10.48 Million ▼ -4318.1%
2022 -0.18x $-29.22 Million $-29.22 Million $166.71 Million ▲ +59.0%
2021 -0.43x $-14.56 Million $-14.56 Million $34.05 Million ▲ +11.8%
2020 -0.48x $-2.46 Million $-2.46 Million $5.08 Million
Financial Flexibility Index = (Operating CF − Capex) / Total Liabilities = Free Cash Flow / Total Liabilities